340 related articles for article (PubMed ID: 33141832)
1. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
[TBL] [Abstract][Full Text] [Related]
2. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
3. Reactive Oxygen Species Production Is a Major Factor Directing the Postantibiotic Effect of Fluoroquinolones in Streptococcus pneumoniae.
García MT; Valenzuela MV; Ferrándiz MJ; de la Campa AG
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160286
[TBL] [Abstract][Full Text] [Related]
4. Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.
Tirado-Vélez JM; Carreño D; Sevillano D; Alou L; Yuste J; de la Campa AG
Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34068007
[TBL] [Abstract][Full Text] [Related]
5. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
6. New alkaloid antibiotics that target the DNA topoisomerase I of Streptococcus pneumoniae.
García MT; Blázquez MA; Ferrándiz MJ; Sanz MJ; Silva-Martín N; Hermoso JA; de la Campa AG
J Biol Chem; 2011 Feb; 286(8):6402-13. PubMed ID: 21169356
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era.
Chen HH; Li HC; Su LH; Chiu CH
J Microbiol Immunol Infect; 2017 Dec; 50(6):839-845. PubMed ID: 27342636
[TBL] [Abstract][Full Text] [Related]
8. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
10. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Pestova E; Millichap JJ; Noskin GA; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
[TBL] [Abstract][Full Text] [Related]
11.
Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
[TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
13. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
14. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
15. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
16. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
[TBL] [Abstract][Full Text] [Related]
17. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
18. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
20. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
